ARTICLE | Clinical News
Maxamine histamine dihydrochloride: Phase II
November 6, 2000 8:00 AM UTC
Preliminary 12-week data from MAXM's trial of the triple combination of Maxamine plus interferon-alpha and ribavirin in patients who did not respond to or relapsed following prior therapy showed that ...